METAP2 inhibitors have previously been clinically shown to have antitumor and antimetastatic effects in patients with late-stage cancer, as well as resensitizing patients to chemotherapy when combined with such agents (3, 17, 18, 26, 27). The gene discussed is METAP2; the disease is cancer.